Journal
EMERGING MICROBES & INFECTIONS
Volume 10, Issue 1, Pages 774-781Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2021.1913973
Keywords
COVID-19; neutralizing antibodies; inactivated SARS-CoV-2; humoral immunity; RBD-ELISA; nucleocapsid-ELISA; S1-ELISA
Categories
Funding
- Saxon State Ministry for Science, Culture and Tourism (grant SaxoCOV)
- European Virus Archive GLOBAL (EVA-GLOBAL) project from the European Union's Horizon 2020 research and innovation program [871029]
Ask authors/readers for more resources
Studying the humoral protective immune response post SARS-CoV-2 infections is crucial for assessing reinfection risk, improving diagnostic methods, and evaluating vaccine trials. This research analyzed the dynamics of neutralizing antibodies and IgG responses in COVID-19 patients, identifying potential diagnostic markers for estimating neutralizing protection.
Monitoring the humoral protective immune response and its durability after SARS-CoV-2 infections is essential for risk assessment of reinfections, the improvement of diagnostic methods and the evaluation of vaccine trials. We have analyzed neutralizing antibodies and IgG responses specific to different antigens, including the inactivated whole-virion of SARS-CoV-2, the spike subunit 1 protein and its receptor binding domain, as well as the nucleocapsid protein. We show the dynamic developments of the responses from the early convalescent stages up to 9 months post symptoms onset in follow-up samples from 57 COVID-19 patients with varying clinical severity. By correlating antibody signals to neutralizing titres, valid diagnostic markers for the estimation of neutralizing protection could be identified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available